Core Viewpoint - Company YaBao Pharmaceutical (600351.SH) has received approval from the National Medical Products Administration for the registration of its product, Sitagliptin Metformin Extended-Release Tablets, which is intended for adult patients with type 2 diabetes [1] Group 1: Product Approval - YaBao's wholly-owned subsidiary, Beijing YaBao Biopharmaceutical Co., Ltd., has been granted the drug registration certificate for Sitagliptin Metformin Extended-Release Tablets (Certificate No: 2025S03027) [1] - The product is designed for adults currently undergoing treatment with a combination of Sitagliptin and Metformin Extended-Release Tablets [1] Group 2: Market Context - Sitagliptin Metformin Extended-Release Tablets were developed by Merck Sharp & Dohme and were approved for sale in the United States in 2012 under the brand name JANUMETXR® [1] - According to data from Minet, the total sales amount for Sitagliptin Metformin Tablets (I), Sitagliptin Metformin Tablets (II), and Sitagliptin Metformin Extended-Release Tablets in China is approximately 921 million RMB for 2024 [1] - Of this total, sales in public hospitals account for 721 million RMB, while retail pharmacies contribute 200 million RMB [1]

Core Viewpoint - The company, Yabao Pharmaceutical (600351.SH), announced that its wholly-owned subsidiary, Beijing Yabao Biopharmaceutical Co., Ltd., has received the drug registration certificate for Sitagliptin Metformin Extended-Release Tablets from the National Medical Products Administration, indicating a significant regulatory approval for a new diabetes treatment [1]. Group 1 - The drug Sitagliptin Metformin Extended-Release Tablets is intended for adult patients with type 2 diabetes who are currently receiving a combination treatment of Sitagliptin and Metformin Extended-Release Tablets [1].

证券代码：600351 证券简称：亚宝药业 公告编号：2025-038 亚宝药业集团股份有限公司 关于全资子公司取得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，亚宝药业集团股份有限公司（以下简称"公司"）全资子公司北京亚 宝生物药业有限公司（以下简称"亚宝生物"）收到了国家药品监督管理局（以 下简称"国家药监局"）核准签发的西格列汀二甲双胍缓释片《药品注册证书》 （证书编号：2025S03027）。现将相关情况公告如下： 一、药品注册证书主要内容 1、药品名称：西格列汀二甲双胍缓释片 2、剂型：片剂 3、规格：磷酸西格列汀 100mg（按 C₁₆H₁₅F₆N₅O 计）与盐酸二甲双胍 1000mg 4、包装规格：30 片/瓶 5、注册分类：化学药品 3 类 8、药品批准文号：国药准字 H20255599 9、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品的其他情况 西格列汀二甲双胍缓释片适用于正在接受西格列汀和二甲双 ...

Core Viewpoint - The announcement highlights that the company's wholly-owned subsidiary, Beijing Yabao Biological Pharmaceutical Co., Ltd., has received the drug registration certificate for Sitagliptin Metformin Extended-Release Tablets from the National Medical Products Administration, indicating a significant milestone for the company in the diabetes treatment market [1] Group 1: Product Approval - The Sitagliptin Metformin Extended-Release Tablets are approved for use in adult patients with type 2 diabetes [1] - The drug was developed by Merck Sharp Dohme and was approved for sale in the United States in 2012 [1] - The expected sales amount for the product in China in 2024 is approximately 921 million RMB [1] Group 2: Market Context - A total of 11 companies have received the registration approval for this drug in China [1] - The company has invested approximately 15.3284 million RMB in research and development for this product [1]

Core Viewpoint - Yabao Pharmaceutical (600351.SH) has repurchased a total of 6 million shares, representing 0.86% of the company's total share capital, with a total expenditure of RMB 38.878 million as of September 30, 2025 [1] Summary by Category - **Share Repurchase Details** - The company has conducted share repurchases through centralized bidding [1] - The highest transaction price was RMB 6.65 per share, while the lowest was RMB 6.30 per share [1] - The total amount paid for the repurchased shares is RMB 38.878 million, excluding transaction fees [1]

证券代码：600351 证券简称：亚宝药业 公告编号：2025-037 亚宝药业集团股份有限公司 关于以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/4/26，由董事会提议 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 5 11 月 | 年 | 月 | 16 | 日~2025 | 年 | 14 日 | | 预计回购金额 | 0.5亿元~1亿元 | | | | | | | | 回购用途 | √减少注册资本 □用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 6,000,000股 | | | | | | | | 累计已回购股数占总股本比例 | 0.86% | | | | | | | | 累计已回购金额 | 38 ...

Core Points - The company announced a share repurchase plan approved at the shareholders' meeting on May 16, 2025, with a repurchase period from May 16, 2025, to November 14, 2025 [1] - The expected repurchase amount is between 50 million to 100 million yuan, aimed at reducing registered capital [1] - As of September 30, the company has repurchased a total of 6 million shares, accounting for 0.86% of the total share capital, with a maximum transaction price of 6.65 yuan per share and a minimum of 6.30 yuan per share, totaling a payment of 38,878,040 yuan [1]

Core Points - On September 29, 2025, the company announced that its controlling shareholder, Yabao Investment, received a notice of pledge release [1] - Yabao Investment repurchased 13,650,000 unrestricted circulating shares that were pledged to Shanxi Securities Co., Ltd. through a stock pledge repurchase transaction [1] - Following the completion of the repurchase transaction, the corresponding shares' pledge was released [1]

| 股东名称 | 亚宝投资 | | --- | --- | | 本次解除质押股份 | 13,650,000 股 | | 占其所持股份比例 | 14.48% | | 占公司总股本比例 | 1.95% | | 解除质押时间 | 2025 年 9 月 26 日 | | 持股数量 | 94,300,000 股 | | 持股比例 | 13.47% | | 剩余被质押股份数量 | 24,950,000 股 | | 剩余被质押股份数量占其所持股份比例 | 26.46% | | 剩余被质押股份数量占公司总股本比例 | 3.56% | 证券代码：600351 证券简称：亚宝药业 公告编号：2025-036 亚宝药业集团股份有限公司 关于控股股东股票质押式回购交易股份提前购回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●截至本公告披露日，亚宝药业集团股份有限公司（以下简称"公司"）控 股股东山西亚宝投资集团有限公司（以下简称"亚宝投资"）持有本公司股份 94,300,000股，占公司总股本的13.47%；本次质押解除后 ...

Core Viewpoint - Yabao Pharmaceutical announced that its controlling shareholder, Yabao Investment, completed the early repurchase of 13,650,000 shares of unrestricted circulating stock through a pledged repurchase transaction on September 26, leading to the release of the corresponding pledge [1] Summary by Relevant Sections - Shareholding Structure - As of the announcement date, Yabao Investment holds 94,300,000 shares, accounting for 13.47% of the total share capital [1] - After the release of the pledge, the total pledged shares amount to 24,950,000, which represents 26.46% of Yabao Investment's total holdings and 3.56% of the company's total share capital [1] - Pledged Shares - Yabao Investment and its concerted parties collectively hold 97,300,000 shares, which is 13.90% of the total shares, with a cumulative pledge of 24,950,000 shares [1] - Company Monitoring - The company will closely monitor the pledge matters and disclose information in a timely manner [1]